Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432F. Wang, Rui‐Hua Xu, Xiaoli Wei et al.|Annals of Oncology|2019Cited by 475
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)Feng‐Hua Wang, Rui‐Hua Xu, Xiaoli Wei et al.|Journal of Clinical Oncology|2021Cited by 350
Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cellsJingyao Tu, Xianglin Yuan|Theranostics|2021Cited by 72
Multiple polymorphisms within the PLCE1 are associated with esophageal cancer via promoting the gene expression in a Chinese Kazakh populationXiaobin Cui, Feng Li, Lei Yang et al.|Gene|2013Cited by 43
The Thr300Ala variant of ATG16L1 is associated with decreased risk of brain metastasis in patients with non-small cell lung cancerQian-xia Li, Xianglin Yuan|Autophagy|2017Cited by 40